Infectious Disease

BenevolentAI, DNDi begin joint AI research project on dengue

BenevolentAI and Drugs for Neglected Disease initiative (DNDi) have commenced a joint AI research project to address dengue.

Merck signs agreement with Thermo Fisher Scientific to manufacture molnupiravir

Merck (MSD outside Canada and the US) has signed an agreement with Thermo Fisher Scientific to manufacture molnupiravir, an investigational oral antiviral medicine to treat Covid-19.

EMA begins rolling review of Valneva’s Covid-19 vaccine candidate VLA2001

The European Medicines Agency (EMA) has begun a rolling review of Valneva’s VLA2001, a whole-virus inactivated, adjuvanted Covid-19 vaccine candidate.

FDA gives expanded EUA for Pfizer-BioNTech Covid-19 vaccine booster dose

The US Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) of a booster dose of the Pfizer-BioNTech Covid-19 vaccine.

Enzolytics, Samsung Biologics partner to develop therapies for HIV, Covid-19

Samsung Biologics and Enzolytics have entered a strategic contract development and manufacturing organization (CDMO) collaboration agreement to develop and produce monoclonal antibody treatments for human immunodeficiency virus (HIV) and Covid-19.

AstraZeneca seeks FDA EUA for antibody cocktail to prevent Covid-19

AstraZeneca has sought Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its AZD7442 to prevent symptomatic Covid-19.

Australia signs agreement for new Covid-19 drug

Australia has signed an agreement for 300,000 courses of molnupiravir, an antiviral pill that has shown signs of reducing deaths and hospitalisations due to Covid-19.

Trevena reports positive results of TRV027 proof-of-concept trial in Covid-19 patients

Trevena has announced positive results from a proof-of-concept clinical trial during which its new AT1 receptor-selective agonist, TRV027, was found to be well-tolerated in Covid-19 patients who have been hospitalised. 

Pfizer-BioNTech reports positive results for Covid-19 vaccine trail in children aged 5 to 11 years

Pfizer and its partner BioNTech have announced positive topline results from a pivotal trial of their Covid-19 vaccine in children aged 5 to 11 years.